Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK119 combined with AK104 in advanced solid tumors
NCT05559541Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Dec 2022
- Primary completion
- May 2024
- Countries
- 1
01
Overview
A Phase 2 trial of drebuxelimab in solid tumor (advanced stage), sponsored by Akeso, Inc.. Started Dec 2022; status: terminated.
02
Drugs
drebuxelimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05559541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559541.